Trial Profile
A Phase I, Randomized, Double-blind, Placebo-controlled Study Evaluating The Safety, Hemodynamic And Neurohumoral Effects of a Novel Chimeric Peptide, CD-NP, in Patients With Left Ventricular Assist
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Cenderitide (Primary)
- Indications Heart failure
- Focus Adverse reactions
- 30 Mar 2020 Results presented at the 2020 Annual Scientific Session of the American College of Cardiology and World Congress of Cardiology
- 16 Nov 2016 Results assessing safety of subcutaneous Cenderitide Co-Therapy With LVAD Support presented at the 89th Annual Scientific Sessions of the American Heart Association (2016).
- 29 Aug 2016 Status changed from recruiting to completed.